Lynparza meets in postapproval Phase III for relapsed ovarian cancer, gets first-line maintenance approval

AstraZeneca plc (LSE:AZN; NYSE:AZN) and partner Merck & Co. Inc. (NYSE:MRK) said on Dec. 20 that Lynparza olaparib met the primary endpoint of improving objective response rate (ORR) vs. physician’s choice of single-agent chemotherapy in the Phase III SOLO-3 trial to treat relapsed BRCA-mutated advanced ovarian cancer. The PARP inhibitor also met the secondary endpoint of improving progression-free survival (PFS) vs. chemotherapy.

The trial results came a day after FDA approved Lynparza for maintenance treatment of adults with germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy...